{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:39:15Z","timestamp":1784885955417,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aimed to determine the risk factors for PIBP in real-world clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>We retrospectively collected the clinical records of patients who received pegfilgrastim to support myelosuppressive chemotherapy with at least a 10% risk of FN between 2015 and 2018 at our center. Patients received pegfilgrastim 3.6\u00a0mg between days 2 and 7 after chemotherapy administration (day 1) for primary or secondary prophylaxis against FN. All adverse events were recorded according to the Common Terminology Criteria for Adverse Events. Patients who experienced intermittent bone pain in the back, femur, or other anatomic sites after the pegfilgrastim administration were considered to have PIBP. To evaluate the relationship between PIBP incidence and patient characteristics, we performed univariate and multivariate logistic regression analyses to calculate the odds ratios (ORs) of possible risk factors for PIBP. We analyzed the data of 305 patients (median age: 63\u00a0years), who underwent 1220 chemotherapy cycles with pegfilgrastim per cycle. Univariate analysis revealed that female sex (vs. male sex), younger age (&lt;\u200955\u00a0years vs.\u2009\u2265\u200955\u00a0years), and solid cancers (vs. hematologic cancers) had significantly higher ORs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). However, only younger age (&lt;\u200955\u00a0years) was an independent risk factor for PIBP on multivariate analysis (OR 3.62, 95% confidence interval 1.51\u20138.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.004).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Younger age (&lt;\u200955\u00a0years) was significantly associated with a higher risk of PIBP among patients receiving chemotherapy with a\u2009\u2265\u200910% risk of FN. Therefore, oncologists should meticulously formulate management plan for PIBP in younger patients after administering pegfilgrastim.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-022-00272-9","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:03:34Z","timestamp":1673366614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience"],"prefix":"10.1186","volume":"9","author":[{"given":"Shinya","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Uchiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ootsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"272_CR1","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199\u2013212. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26169616. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488.","journal-title":"J Clin Oncol"},{"key":"272_CR2","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00520-017-3842-1","volume":"25","author":"M Aapro","year":"2017","unstructured":"Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017;25:3295\u2013304. https:\/\/doi.org\/10.1007\/s00520-017-3842-1.","journal-title":"Support Care Cancer"},{"key":"272_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","volume":"51","author":"DC Moore","year":"2017","unstructured":"Moore DC, Pellegrino AE. Pegfilgrastim-induced bone pain: A review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797\u2013803. https:\/\/doi.org\/10.1177\/1060028017706373.","journal-title":"Ann Pharmacother"},{"key":"272_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five \u201cWs\u201d for bone pain due to the administration of granulocyte-Colony Stimulating Factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89:112\u201328. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.006.","journal-title":"Crit Rev Oncol Hematol"},{"key":"272_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdg019.","journal-title":"Ann Oncol"},{"key":"272_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","volume":"30","author":"JJ Kirshner","year":"2012","unstructured":"Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C, et al. Prevention of pegfilgrastim-induced bone pain: A phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester cancer center clinical community oncology Program research base. J Clin Oncol. 2012;30:1974\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.8364.","journal-title":"J Clin Oncol"},{"key":"272_CR7","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","volume":"23","author":"N Masuda","year":"2015","unstructured":"Masuda N, Tokuda Y, Nakamura S, Shimazaki R, Ito Y, Tamura K. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer. 2015;23:2891\u20138. https:\/\/doi.org\/10.1007\/s00520-015-2654-4.","journal-title":"Support Care Cancer"},{"key":"272_CR8","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00520-016-3119-0","volume":"24","author":"J Moukharskaya","year":"2016","unstructured":"Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K, et al. Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim [Internet]. Support Care Cancer. 2016;24:3085\u201393. https:\/\/doi.org\/10.1007\/s00520-016-3119-0.","journal-title":"Support Care Cancer"},{"key":"272_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00520-015-2834-2","volume":"24","author":"H Xu","year":"2016","unstructured":"Xu H, Gong Q, Vogl FD, Reiner M, Page JH. Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer. 2016;24:723\u201330. https:\/\/doi.org\/10.1007\/s00520-015-2834-2.","journal-title":"Support Care Cancer"},{"key":"272_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355. https:\/\/doi.org\/10.1097\/00000421-198212000-00014.","journal-title":"Am J Clin Oncol"},{"key":"272_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11096-018-0667-z","volume":"40","author":"T Hayama","year":"2018","unstructured":"Hayama T, Sakurai K, Miura K, Washinosu S, Tsuboi S, Uchiike A, et al. Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. Int J Clin Pharm. 2018;40:997\u20131000. https:\/\/doi.org\/10.1007\/s11096-018-0667-z.","journal-title":"Int J Clin Pharm"},{"key":"272_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1097\/j.pain.0000000000000294","volume":"156","author":"T Graven-Nielsen","year":"2015","unstructured":"Graven-Nielsen T, Vaegter HB, Finocchietti S, Handberg G, Arendt-Nielsen L. Assessment of musculoskeletal pain sensitivity and temporal summation by cuff pressure algometry: a reliability study. Pain. 2015;156:2193\u2013202. https:\/\/doi.org\/10.1097\/j.pain.0000000000000294.","journal-title":"Pain"},{"key":"272_CR13","doi-asserted-by":"publisher","unstructured":"Bujang MA, Sa\u2019at N, Tg Abu Bakar Sidik TMI, Lim CJ. Sample size guidelines for logistic regression from observational studies with large population: Emphasis on the accuracy between statistics and parameters based on real life clinical data. Malays J Med Sci. 2018;25:122\u201330. https:\/\/doi.org\/10.21315\/mjms2018.25.4.12","DOI":"10.21315\/mjms2018.25.4.12"}],"updated-by":[{"DOI":"10.1186\/s40780-023-00284-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000}}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-022-00272-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-022-00272-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T10:11:15Z","timestamp":1681467075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-022-00272-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/s40780-022-00272-9","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40780-023-00284-z","asserted-by":"object"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40780-023-00284-z","URL":"https:\/\/doi.org\/10.1186\/s40780-023-00284-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. All patients provided informed consent for chemotherapy and supportive therapies, including prophylaxis for FN using pegfilgrastim. The Nihon University Itabashi Hospital Clinical Research Judging Committee approved the data collection, analysis, and publication of this study on July 11, 2018 (RK-180710\u201317).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was not required owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Katsuhiro Miura received speaker fees from Kyowa-Kirin, which manufactures pegfilgrastim in Japan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}